Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

PKM2 is not required for colon cancer initiated by APC loss.

Lau AN, Israelsen WJ, Roper J, Sinnamon MJ, Georgeon L, Dayton TL, Hillis AL, Yilmaz OH, Di Vizio D, Hung KE, Vander Heiden MG.

Cancer Metab. 2017 Nov 30;5:10. doi: 10.1186/s40170-017-0172-1. eCollection 2017.

2.

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.

Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.

PMID:
25389372
3.

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.

Belmont PJ, Budinska E, Jiang P, Sinnamon MJ, Coffee E, Roper J, Xie T, Rejto PA, Derkits S, Sansom OJ, Delorenzi M, Tejpar S, Hung KE, Martin ES.

Dis Model Mech. 2014 Jun;7(6):613-23. doi: 10.1242/dmm.013904. Epub 2014 Apr 17.

4.

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz ÖH, Bronson RT, Martin ES, Tsichlis PN, Hung KE.

Cancer Lett. 2014 Jun 1;347(2):204-11. doi: 10.1016/j.canlet.2014.02.018. Epub 2014 Feb 24.

5.

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.

Clin Cancer Res. 2013 May 15;19(10):2688-98. doi: 10.1158/1078-0432.CCR-12-2556. Epub 2013 Apr 2. Erratum in: Clin Cancer Res. 2013 Jul 15;19(14):4018.

6.

Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.

Martin ES, Belmont PJ, Sinnamon MJ, Richard LG, Yuan J, Coffee EM, Roper J, Lee L, Heidari P, Lunt SY, Goel G, Ji X, Xie Z, Xie T, Lamb J, Weinrich SL, VanArsdale T, Bronson RT, Xavier RJ, Vander Heiden MG, Kan JL, Mahmood U, Hung KE.

Clin Cancer Res. 2013 Jun 1;19(11):2929-40. doi: 10.1158/1078-0432.CCR-12-2307. Epub 2013 Feb 12.

7.

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.

Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, Sinnamon MJ, Lee L, Chen PC, Bronson RT, Martin ES, Hung KE.

PLoS One. 2011;6(9):e25132. doi: 10.1371/journal.pone.0025132. Epub 2011 Sep 26.

8.

Essential role for mast cell tryptase in acute experimental colitis.

Hamilton MJ, Sinnamon MJ, Lyng GD, Glickman JN, Wang X, Xing W, Krilis SA, Blumberg RS, Adachi R, Lee DM, Stevens RL.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):290-5. doi: 10.1073/pnas.1005758108. Epub 2010 Dec 20.

9.

Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse.

Sinnamon MJ, Carter KJ, Fingleton B, Matrisian LM.

Int J Exp Pathol. 2008 Dec;89(6):466-75. doi: 10.1111/j.1365-2613.2008.00621.x.

10.

A protective role of mast cells in intestinal tumorigenesis.

Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM.

Carcinogenesis. 2008 Apr;29(4):880-6. doi: 10.1093/carcin/bgn040. Epub 2008 Feb 6.

PMID:
18258601

Supplemental Content

Loading ...
Support Center